INSIGHTEC ANNOUNCES $150M FINANCING TO FUND CONTINUED GROWTH

Fidelity Management & Research Company Leads Financing; Nexus Neurotech Ventures and Ally Bridge Group Co-Lead Robust Investor Syndicate

HAIFA, Israel and MIAMI, June 18, 2024 /PRNewswire/ — Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced it has raised $150 million in equity financing. The round was led by Fidelity Management & Research Company and co-led by Nexus Neurotech Ventures and Ally Bridge Group. Support from new investors, Baillie Gifford, Catalio Capital Management, Fayez Sarofim & Co., and Gilmartin Capital, along with strong support from insiders, led by affiliates of York Global Finance / Community Fund and Perceptive Advisors generated an oversubscribed round.

“We are grateful for the strong support of our mission from these new and existing investors,” said Maurice R Ferré, M.D., CEO and chairman of the board of Insightec. “This financing provides Insightec with runway to expand incisionless neurosurgery to the many patients suffering from movement disorders and continue to make calculated and strategic investments in new indications.”

With over 160 systems installed worldwide, Insightec’s proprietary technology has been used in nearly 20,000 commercial applications and is currently FDA approved as an incisionless, immediate treatment for patients suffering from essential tremor and Parkinson’s disease.

About Insightec

Insightec is a global healthcare company creating the next generation of patient care by realizing the therapeutic power of focused ultrasound. The company’s Exablate Prime platform focuses sound waves, safely guided by MRI, to provide tremor treatment to patients with medication-refractory essential tremor and Parkinson’s disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. Insightec is headquartered in Haifa, Israel, and Miami, with offices in Dallas, Shanghai, and Tokyo.

Forward-looking Statements:

This document contains forward-looking statements regarding, among other things, plans, expectations, and future events. In some cases, forward-looking statements can be identified by the following words: “may,” “can,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “promise,” “continue,” “ongoing,” or the negative of these terms. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. Any forward-looking statement is based on information available to Insightec as of the date of the statement. All written or oral forward-looking statements attributable to Insightec are qualified by this caution. Insightec does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Insightec’s expectations.

“Exablate,” and “Exablate Prime,” as well as the “INSIGHTEC” logo, whether standing alone or in connection with the word “Insightec,” are protected trademarks of Insightec.

Logo: https://healthtechnologynet.com/wp-content/uploads/2024/06/Insightec_Logo-1.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/insightec-announces-150m-financing-to-fund-continued-growth-302176098.html

SOURCE Insightec